Phenprocoumon
Phenprocoumon is a long-acting oral anticoagulant of the 4-hydroxycoumarin class that inhibits vitamin K epoxide reductase, thereby preventing the regeneration of reduced vitamin K needed for the carboxylation of clotting factors II, VII, IX, and X. It is widely used in several European countries for the prevention and treatment of thromboembolic disorders including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Molekularmasse
280,3000 g/mol
LogP
3,60
TPSA
46,50 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O
InChI
InChI=1S/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3
Molecular Formula
C18H16O3
HBD / HBA
1 / 3
Rotierbare Bindungen
3
Schwere Atome
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Phenprocoumon is a long-acting oral anticoagulant of the 4-hydroxycoumarin class that inhibits vitamin K epoxide reductase, thereby preventing the regeneration of reduced vitamin K needed for the carboxylation of clotting factors II, VII, IX, and X. It is widely used in several European countries for the prevention and treatment of thromboembolic disorders including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.
Serves as an essential micronutrient cofactor in various enzymatic reactions and metabolic processes. Supplementation corrects deficiency states and supports normal physiological function.
Yes, Phenprocoumon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1465. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54680692. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="phenprocoumon"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/phenprocoumon/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/phenprocoumon/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/phenprocoumon/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="phenprocoumon"></drugfyi-drug>